JCR Pharmaceuticals Announces Executive Appointments and Leadership Transition Effective April 1, 2026

on

JCR Pharmaceuticals announced on May 13, 2025, a leadership transition effective April 1, 2026:
Toru Ashida becomes Representative Director Chairman, Hiroyuki Sonoda becomes Representative Director President, and Shin Ashida transitions to Director, Founder.1

Toru Ashida (born 1968) is currently Director, Senior Managing Executive Officer, Sales; holds 360,308 shares.1

Hiroyuki Sonoda (born 1978, Ph.D.) is currently Director, Senior Managing Executive Officer, Research; holds 68,320 shares; also President of AlliedCel Corporation.1

The changes aim to strengthen management structure amid the company's 50th anniversary and drive long-term value; other executive appointments pending.1

JCR Pharmaceuticals (TSE 4552) specializes in therapies for rare and genetic diseases with global expansion.1

Sources:

1. https://jcrpharm.com/jcr-pharmaceuticals-announces-chairman-and-president-transition-as-of-april-1-2026/